I would feel less concerned with selling product coming out from a PQ run, since at that stage the tolerance window of process parameters may have already been defined and probably even documented since it happens after the OQ.
I agree with you that this is a decicion that involves risk...as may involve cost as well.
If we have worries with selling out products from a PQ, it would then be more risky if they come from an OQ.
I did a quick sampling of 483's on the FDA data base of Warning letters and could not find any instance of companies being penalized for doing, so, but that does not mean that the risk does not exist.
Thank you all for sharing